MoneyWorks4Me

Lupin receives USFDA’s nod for Mycophenolic Acid Delayed-Release Tablets

19 Dec 2019 Evaluate

Lupin has received approval for its Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg from the United States Food and Drug Administration (USFDA) to market a generic equivalent of Myfortic Delayed-Release Tablets, 180 mg and 360 mg, of Novartis Pharmaceuticals Corporation.  Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg (RLD: Myfortic) had an annual sales of approximately $174 million in the U.S. (IQVIA MAT Sept ember 2019).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2104.60 -30.40 (-1.42%)
04-Sep-2026 15:03 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1901.60
Dr. Reddys Labs. 1156.05
Cipla 1378.00
Lupin 2104.60
Zydus Lifesciences 1125.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: